New Bayer site to make traditional Chinese and Western consumer health meds

Bayer snapped up China's Dihon in 2014 with the idea of combining Dihon's traditional Chinese medicines with Bayer's Western OTC products in a major consumer health play in the country. Now it has a large new plant there to produce both kinds of products. Last week, the drugmaker opened the first phase of a CNY 1.4 billion ($213 million), plant, which at 111,534 square meters (1,200,542 square feet) is Bayer's second largest OTC facility in the Asia Pacific. It will soon be producing Bayer's key TCM product, Dan E Fu Kang, which is marketed as a gynecological medicine for women's health indications including dysmenorrhea. More from FiercePharmaManufacturing | More

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.